Trials
1 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Intramuscular injection. Injections should be given in the deltoid muscle, using the same non-dominant arm for all IMP doses.”In the company’s words, NCT07379580 on ClinicalTrials.gov
- Tested for
- Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection
- Main trialPhase 2
- “This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.”In the company’s words, NCT07379580 on ClinicalTrials.gov
Other drugs for Smallpox
- TecovirimatSIGA Technologies · Phase 2
- BSY001China National Biotec Group Company Limited · Phase 1
Coming up1
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jun 2027 | A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa | |
| Phase 1/2Completed | 25 Aug 2025 | A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026